SIREN : 910486083
FDA is a French company founded 4 years ago, specialized in the sector Restauration traditionnelle. Based in LE BLANC-MESNIL (93150), this company of category PME shows in 2023 a revenue of 902 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2023 |
|---|---|
| Revenue | 901 912 € |
| Net income | 34 178 € |
| EBITDA | 33 446 € |
| Net margin | 3.8% |
In 2023, FDA achieves revenue of 902 k€. After deducting consumption (819 k€), gross margin stands at 83 k€, i.e. a rate of 9%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 33 k€, representing 3.7% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 34 k€, i.e. 3.8% of revenue. This profit can be retained or distributed to shareholders.
901 912 €
83 246 €
33 446 €
56 219 €
34 178 €
3.7%
The debt ratio (= Financial debt / Equity x 100) stands at 1011%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 7%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 40.5 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 1.2% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
1010.788%
7.216%
1.222%
40.529
98.4%
In 2023, the debt ratio of FDA (1010.79) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2023, the financial autonomy of FDA (7.2%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2023, the repayment capacity of FDA (40.53) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 53.35. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 47.9x. Operating income very largely covers interest expenses: high safety margin.
53.355
47.868
In 2023, the liquidity ratio of FDA (53.35) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2023, the interest coverage of FDA (47.9x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 84 days. Excellent situation: suppliers finance 84 days of the operating cycle (retail model). WCR is negative (-27 days): operations structurally generate cash.
-68 626 €
0 j
84 j
0 j
-27 j
Based on 689 transactions of similar company sales in 2023, the value of FDA is estimated at 329 259 € (range 182 256€ - 582 548€). With an EBITDA of 33 446€, the sector multiple of 6.3x is applied. The price/revenue ratio is 0.66x (in line with sector norms). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 689 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare FDA with other companies in the same sector:
Voir toutes les statistiques du secteur Restauration traditionnelle
The revenue of FDA in 2023 is 902 k€.
Yes, FDA generated a net profit of 34 k€ in 2023.
The headquarters of FDA is located in LE BLANC-MESNIL (93150), in the department Seine-Saint-Denis.
The tax return of FDA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
FDA operates in the sector Restauration traditionnelle (NAF code 56.10A). See the 'Sector positioning' section above to compare the company with its competitors.